Abstract
PurposeThe manifestations and complications of SARS-CoV-2 infection in solid organ transplant are poorly known. Lung Transplant group is an immunocompromised group with a shock organ of COVID-19. For this, we analyze the possible risk factors associated with an unfavorable outcomeMethodsRetrospective study between the period march 2020 until june 2021. We analysed the database of Lung Transplant and medical records. It included all patients with a confirmed diagnosis of COVID-19 in our cohort with RT-PCR SARS-COV-2 or rapid test and chest computed tomography compatible. We analyzed demographic features and outcomes: sex; type of transplant (unilateral or bilateral); presence of chronic graft dysfunction; transplant time; confirmed prior rejections; history of SAH and/or DM; nosocomial transmission infection; report of fever and/or dyspnea; need for hospitalization and/or ICU; use of an O2 nasal catheter and/or mechanical ventilation; need of dyalisis; associated bronchopneumonia (confirmed by culture); and previous use of 2 or more immunosuppressants. Statistical analysis was performed and multivariate analysisResultsIn our cohort, we had 213 patients in follow-up (March 2020) and during this period 29 (13.6%) patients with COVID-19 were evaluated. These 23 with diagnosis and supervised treatment in our service and 6 patients in external follow-up of the infectious condition. Overall death was 31% (9).The mean age of patients is 46 years (±15.66), being 51.8% male and 48.2% female. A multivariate analysis, only dialysis (HR 9.186 - CI 1.804-46.758 - p=0.008) and bronchopneumonia (HR 7.554 - CI 1.510-37.790 - p=0.014) are associated with a negative outcome.ConclusionThe lethality is high in this group of patients. Our data was shown that dialysis and bronchopneumonia are associated with a higher risk of death in this group of patients infected with COVID-19. We emphasize that the limitation of this work is mainly due to the small sample analyzed. We suggest more studies are necessary.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
